Key Insights

Highlights

Treatment Research

2 treatments under study, led by Algucosidase Alfa 20 Mgkg Once Every 4 Weeks Instead Of Once Every 2 Weeks

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Active Not Recruiting1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT03694561Active Not Recruiting

Developing a Management Approach for Patients With "Late-Onset" Pompe Disease

NCT06575829Phase 4Not Yet Recruiting

Treatment Frequency Reduction in Pompe Disease

Showing all 2 trials

Research Network

Common Treatments

  • Algucosidase Alfa 20 Mgkg Once Every 4 Weeks Instead Of Once Every 2 Weeks1
  • Observational1

Active Sponsors

  • Erasmus Medical Center1
  • Genzyme, a Sanofi Company1
  • Duke University1

Top Investigators

Related Conditions

  • Pompe Disease Lateonset2
  • Glycogen Storage Disease Type Ii1
  • Pompe Disease1
  • Acid Maltase Deficiency1

Activity Timeline